Key statistics
As of last trade AnaptysBio Inc (AN6:FRA) traded at 44.40, -5.93% below its 52-week high of 47.20, set on Feb 13, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 44.40 |
|---|---|
| High | 44.40 |
| Low | 44.40 |
| Bid | 44.40 |
| Offer | 45.20 |
| Previous close | 44.40 |
| Average volume | 14.29 |
|---|---|
| Shares outstanding | 27.69m |
| Free float | 26.02m |
| P/E (TTM) | -- |
| Market cap | 1.47bn USD |
| EPS (TTM) | -2.82 USD |
Data delayed at least 15 minutes, as of Feb 16 2026 16:00 GMT.
More ▼
- Anaptys Announces Participation at Upcoming Investor Conferences
- Anaptys Files Motion to Dismiss Tesaro’s Claim of Anticipatory Breach of Contract in Ongoing Litigation Against Tesaro, a GSK subsidiary
- Anaptys to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Anaptys Announces Participation in December Investor Conferences
- Anaptys Announces $100 Million Stock Repurchase Plan
- Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
- Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis
- Anaptys Announces Participation in November Investor Conferences
- Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
- Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
More ▼
